Kestra Medical Technologies vs Orchestra BioMed
KMTS and OBIO side by side, both in surgical, medical, and dental instruments and supplies. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How KMTS and OBIO compare
Kestra Medical Technologies is the larger company, worth 3.9 times as much as Orchestra BioMed ($1.7B against $436M).
Orchestra BioMed grew revenue faster over the last twelve months (1007% versus 60.7% for Kestra Medical Technologies).
Kestra Medical Technologies keeps more of each dollar of sales as profit, with a net margin of −140% compared with −183% at Orchestra BioMed.
Orchestra BioMed scores higher on the StockData Score (9 against 5 for Kestra Medical Technologies), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | KMTS | OBIO |
|---|---|---|
| Size and price | ||
| Market cap | $1.7B | $436M |
| Share price | $28.64 | $7.25 |
| Change, 1 year | 6.9% | 64.0% |
| Change, 5 years | – | −26.5% |
| Beta (5Y) | 1.21 | 0.84 |
| Employees | 443 | 86 |
| StockData Score | ||
| Total score | 5 | 9 (better) |
| Valuation score | 0 | 0 |
| Growth score | 3 | 3 |
| Performance score | 0 | 1 (better) |
| Health score | 2 | 5 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 16.0× | 14.0× (better) |
| FCF yield | −7.2% (better) | −14.7% |
| Growth | ||
| Revenue growth (TTM) | 60.7% | 1007% (better) |
| Profitability | ||
| Gross margin | 53.9% | 99.6% (better) |
| Operating margin | −134% (better) | −195% |
| Net margin | −140% (better) | −183% |
| FCF margin | −115% (better) | −206% |
| Financial health | ||
| Interest coverage | −19.0× | – |
| Current ratio | 4.69 | 7.25 (better) |
| Altman Z-score | 4.94 (better) | −3.18 |
| Piotroski F-score | 4 | 6 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 98.6% | 46.1% |
| Held by insiders | 44.0% | 56.6% |
| Insider net buying, 12 months | −$15.3M | $6.1M (better) |
| Short interest, % of float | 12.3% | 10.5% |
Go deeper
- KMTS stock overview
- KMTS income statement
- KMTS valuation and score
- OBIO stock overview
- OBIO income statement
- OBIO valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.